Carregant...

Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment

The BRAF inhibitor vemurafenib is currently used for treating patients with BRAF V600E mutant melanoma. However, the responses to vemurafenib are generally partial and of relatively short duration. Recent evidence suggests that activation of the epidermal growth factor receptor (EGFR)/erbB signaling...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Melanoma Res
Autors principals: Ng, Yuen-Keng, Lee, Jia-Ying, Supko, Kathryn M., Khan, Ayesha, Torres, Salina M., Berwick, Marianne, Ho, Jonhan, Kirkwood, John M., Siegfried, Jill M., Stabile, Laura P.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394744/
https://ncbi.nlm.nih.gov/pubmed/24709886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000060
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!